Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a generally positive view: Eleven brokerages give Enliven Therapeutics a consensus “Moderate Buy” rating, with ten buys and one sell. The average 12-month price target is $74.44 versus a recent price of $46.97.
• Enliven’s latest quarterly loss was wider than expected, with EPS of $(0.49) versus the consensus estimate of $(0.39). Analysts expect a full-year loss of approximately $1.75 per share.
• Institutional ownership is substantial at 95.08%; BlackRock and other investment firms recently added or expanded positions, while insiders sold $11.0 million in stock over the past three months under pre-arranged trading plans.

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have received an average rating of "Moderate Buy" from the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $74.44.

ELVN has been the subject of several research analyst reports. Wall Street Zen downgraded Enliven Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Mizuho boosted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. Morgan Stanley initiated coverage on Enliven Therapeutics in a report on Friday. They issued an "overweight" rating and a $70.00 target price on the stock. HC Wainwright raised their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, July 9th. Finally, The Goldman Sachs Group lifted their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th.

Enliven Therapeutics Trading Up 1.6%

ELVN stock opened at $46.97 on Friday. The company's 50-day moving average price is $55.23 and its 200 day moving average price is $47.25. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32. The company has a market cap of $3.44 billion, a P/E ratio of -28.13 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, equities research analysts expect that Enliven Therapeutics will post -1.75 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the company's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the sale, the chief financial officer owned 38,000 shares of the company's stock, valued at $1,913,300. This represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 186,849 shares of company stock worth $11,038,275. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Enliven Therapeutics during the 2nd quarter valued at $221,255,000. Polar Capital Holdings Plc raised its holdings in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company's stock worth $54,111,000 after acquiring an additional 418,673 shares during the last quarter. First Light Asset Management LLC lifted its position in shares of Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock valued at $69,058,000 after acquiring an additional 1,158,883 shares in the last quarter. Rock Springs Capital Management LP lifted its position in shares of Enliven Therapeutics by 3.5% in the first quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company's stock valued at $32,399,000 after acquiring an additional 28,095 shares in the last quarter. Finally, Siren L.L.C. acquired a new stake in shares of Enliven Therapeutics during the first quarter valued at $29,252,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc NASDAQ: ELVN is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.